The Latest Analyst Ratings for Medicenna Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on Medicenna Therapeutics (NASDAQ:MDNA) stock. The average price target is $2.62, implying an upside from the current price of $0.3831. This represents a 67.25% decrease from the previous average price target of $8.00.

August 14, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have a bullish outlook on Medicenna Therapeutics, with an average price target of $2.62, indicating potential growth from the current price.
The bullish outlook from analysts indicates a positive sentiment towards the stock. The average price target of $2.62 is significantly higher than the current price, suggesting potential growth. However, it's worth noting that this target is a 67.25% decrease from the previous target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100